Cross-Talk between PPARγ and insulin signaling and modulation of Insulin Sensitivity

PPAR Research

Volumn , Issue , 2009, Pages

  Giorgino, Francesco ^a   Leonardini, Anna ^a   Laviola, Luigi ^a   Perrini, Sebastio ^a   Natalicchio, Annalisa ^a  

^a UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHOXY 3 [4 [5 (4 PHENOXY)PENT 1 YNYL]PHENYL] PROPIONIC ACID; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 5 (2,4 DIOXO 5 THIAZOLIDINYLMETHYL) 2 METHOXY N [4 (TRIFLUOROMETHYL)BENZYL]BENZAMIDE; ADENYLATE KINASE; ARYLMANDELIC ACID; CYTOKINE; FATTY ACID; GLITAZONE DERIVATIVE; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; INSULIN RECEPTOR; INSULIN RECEPTOR SUBSTRATE 1; LSN 862; LY 465608; METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PHOSPHATIDYLINOSITOL 3 KINASE; PIOGLITAZONE; PROTEIN KINASE B; RAGAGLITAZAR; RETINOID X RECEPTOR; ROSIGLITAZONE; TRANSFORMING GROWTH FACTOR BETA1; TROGLITAZONE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADIPOCYTE; ADIPOGENESIS; ADIPOSE TISSUE; CELL DIFFERENTIATION; CELL MATURATION; CYTOKINE RELEASE; DIABETES MELLITUS; DRUG EFFICACY; EDEMA; ENERGY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FRACTURE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HOMEOSTASIS; HUMAN; INSULIN SENSITIVITY; LIPID METABOLISM; LIVER; MISSENSE MUTATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; UNSPECIFIED SIDE EFFECT;

EID: 77749295756     PISSN: 16874757     EISSN: 16874765     Source Type: Journal    
DOI: 10.1155/2009/818945     Document Type: Review

References (116)

1. Tontonoz P., Hu E., Graves R. A., Budavari A. I., Spiegelman B. M., mPPARγ2: tissue-specific regulator of an adipocyte enhancer Genes and Development 1994 8 10 1224 1234
2. Berger J., Patel H. V., Woods J. et al., A PPAR mutant serves as a dominant negative inhibitor of PPAR signaling and is localized in the nucleus Molecular and Cellular Endocrinology 2000 162 1-2 57 67
3. Nolte R. T., Wisely G. B., Westin S. et al., Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ Nature 1998 395 6698 137 143
4. Yang W., Rachez C., Freedman L. P., Discrete roles for peroxisome proliferator-activated receptor and retinoid X receptor in recruiting nuclear receptor coactivators Molecular and Cellular Biology 2000 20 21 8008 8017
5. Hansen M. K., Connolly T. M., Nuclear receptors as drug targets in obesity, dyslipidemia and atherosclerosis Current Opinion in Investigational Drugs 2008 9 3 247 255
6. Kota B. P., Huang T. H.-W., Roufogalis B. D., An overview on biological mechanisms of PPARs Pharmacological Research 2005 51 2 85 94
7. Billin A. N., PPAR- / agonists for type 2 diabetes and dyslipidemia: an adopted orphan still looking for a home Expert Opinion on Investigational Drugs 2008 17 10 1465 1471
8. Zieleniak A., Wjcik M., Woniak L. A., Structure and physiological functions of the human peroxisome proliferator-activated receptor γ Archivum Immunologiae et Therapiae Experimentalis 2008 56 5 331 345
9. Forman B. M., Chen J., Evans R. M., Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors and Proceedings of the National Academy of Sciences of the United States of America 1997 94 9 4312 4317
10. Kliewer S. A., Sundseth S. S., Jones S. A. et al., Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ Proceedings of the National Academy of Sciences of the United States of America 1997 94 9 4318 4323
11. Krey G., Braissant O., LHorset F. et al., Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay Molecular Endocrinology 1997 11 6 779 791
12. 2 is a ligand for the adipocyte determination factor PPARγ Cell 1995 83 5 803 812
13. 2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation Cell 1995 83 5 813 819
14. Nagy L., Tontonoz P., Alvarez J. G. A., Chen H., Evans R. M., Oxidized LDL regulates macrophage gene expression through ligand activation of PPARγ Cell 1998 93 2 229 240
15. Zhang C., Baker D. L., Yasuda S. et al., Lysophosphatidic acid induces neointima formation through PPARγ activation Journal of Experimental Medicine 2004 199 6 763 774
16. Schopfer F. J., Lin Y., Baker P. R. S.et al., Nitrolinoleic acid: an endogenous peroxisome proliferator-activated receptor γ ligand Proceedings of the National Academy of Sciences of the United States of America 2005 102 7 2340 2345
17. Lehmann J. M., Lenhard J. M., Oliver B. B., Ringold G. M., Kliewer S. A., Peroxisome proliferator-activated receptors α and γ are activated by indomethacin and other non-steroidal anti-inflammatory drugs Journal of Biological Chemistry 1997 272 6 3406 3410
18. Kletzien R. F., Clarke S. D., Ulrich R. G., Enhancement of adipocyte differentiation by an insulin-sensitizing agent Molecular Pharmacology 1992 41 2 393 398
19. Willson T. M., Cobb J. E., Cowan D. J. et al., The structureactivity relationship between peroxisome proliferator-activated receptor γ agonism and the antihyperglycemic activity of thiazolidinediones Journal of Medicinal Chemistry 1996 39 3 665 668
20. Reifel-Miller A., Otto K., Hawkins E. et al., A peroxisome proliferator-activated receptor α/γ dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia Molecular Endocrinology 2005 19 6 1593 1605
21. Lu I.-L., Huang C.-F., Peng Y.-H. et al., Structure-based drug design of a novel family of PPAR γpartial agonists: virtual screening, X-ray crystallography, and in vitro/in vivo biological activities Journal of Medicinal Chemistry 2006 49 9 2703 2712
22. Xu H. E., Lambert M. H., Montana V. G.et al., Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors Proceedings of the National Academy of Sciences of the United States of America 2001 98 24 13919 13924
23. Adams A. D., Hu Z., von Langen D.et al., O-arylmandelic acids as highly selective human PPAR α/γ agonists Bioorganic and Medicinal Chemistry Letters 2003 13 19 3185 3190
24. Chakrabarti R., Vikramadithyan R. K., Misra P. et al., Ragaglitazar: a novel PPARα PPARγ agonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models British Journal of Pharmacology 2003 140 3 527 537
25. Wolf G., The function of the nuclear receptor peroxisome proliferator-activated receptor delta in energy homeostasis Nutrition Reviews 2003 61 11 387 390
26. Kim Y.-B., Ciaraldi T. P., Kong A.et al., Troglitazone but not metformin restores insulin-stimulated phosphoinositide 3-kinase activity and increases p110β protein levels in skeletal muscle of type 2 diabetic subjects Diabetes 2002 51 2 443 448
27. 3 is defective in muscle in type 2 diabetes and impaired glucose tolerance: amelioration by rosiglitazone and exercise Diabetes 2003 52 8 1926 1934
28. Karlsson H. K. R., Hllsten K., Bjrnholm M. et al., Effects of metformin and rosiglitazone treatment on insulin signaling and glucose uptake in patients with newly diagnosed type 2 diabetes: a randomized controlled study Diabetes 2005 54 5 1459 1467
29. Musi N., Hirshman M. F., Nygren J. et al., Metformin increases AMP-activated protein-kinase activity in skeletal muscle of subjects with type 2 diabetes Diabetes 2002 51 7 2074 2081
30. Ciaraldi T. P., Kong A. P. S., Chu N. V. et al., Regulation of glucose transport and insulin signaling by troglitazone or metformin in adipose tissue of type 2 diabetic subjects Diabetes 2002 51 1 30 36
31. Meyer M. M., Levin K., Grimmsmann T.et al., Troglitazone treatment increases protein kinase B phosphorylation in skeletal muscle of normoglycemic subjects at risk for the development of type 2 diabetes Diabetes 2002 51 9 2691 2697
32. Miyazaki Y., He H., Mandarino L. J., DeFronzo R. A., Rosiglitazone improves downstream insulin receptor signaling in type 2 diabetic patients Diabetes 2003 52 8 1943 1950
33. Coletta D. K., Sriwijitkamol A., Wajcberg E. et al., Pioglitazone stimulates AMP-activated protein kinase signalling and increases the expression of genes involved in adiponectin signalling, mitochondrial function and fat oxidation in human skeletal muscle in vivo: a randomised trial Diabetologia 2009 52 4 723 732
34. Hammarstedt A., Andersson C. X., Rotter Sopasakis V., Smith U., The effect of PPARγ ligands on the adipose tissue in insulin resistance Prostaglandins Leukotrienes and Essential Fatty Acids 2005 73 1 65 75
35. Hammarstedt A., Sopasakis V. R., Gogg S., Jansson P.-A., Smith U., Improved insulin sensitivity and adipose tissue dysregulation after short-term treatment with pioglitazone in non-diabetic, insulin-resistant subjects Diabetologia 2005 48 1 96 104
36. Jiang G., Dallas-Yang Q., Biswas S., Li Z., Zhang B. B., Rosiglitazone, an agonist of peroxisome-proliferator-activated receptor γ (PPARγ), decreases inhibitory serine phosphorylation of IRS1 in vitro and in vivo Biochemical Journal 2004 377 2 339 346
37. Griffin M. E., Marcucci M. J., Cline G. W. et al., Free fatty acid-induced insulin resistance is associated with activation of protein kinase C theta and alterations in the insulin signaling cascade Diabetes 1999 48 6 1270 1274
38. Jiang G., Dallas-Yang Q., Li Z. et al., Potentiation of insulin signaling in tissues of Zucker obese rats after acute and long-term treatment with PPAR agonists Diabetes 2002 51 8 2412 24 19
39. Smith U., Gogg S., Johansson A., Olausson T., Rotter V., Svalstedt B., Thiazolidinediones (PPARγ agonists) but not PPARα agonists increase IRS-2 gene expression in 3T3-L1 and human adipocytes The FASEB Journal 2001 15 1 215 220
40. Zhou G., Myers R., Li Y.et al., Role of AMP-activated protein kinase in mechanism of metformin action Journal of Clinical Investigation 2001 108 8 1167 1174
41. Zhang B., Berger J., Zhou G. et al., Insulin- and mitogen-activated protein kinase-mediated phosphorylation and activation of peroxisome proliferator-activated receptor γ Journal of Biological Chemistry 1996 271 50 31771 31774
42. Adams M., Reginato M. J., Shao D., Lazar M. A., Chatterjee V. K., Transcriptional activation by peroxisome proliferator-activated receptor γ is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site Journal of Biological Chemistry 1997 272 8 5128 5132
43. Camp H. S., Tafuri S. R., Leff T., c-jun N-terminal kinase phosphorylates peroxisome proliferator-activated receptor- 1 and negatively regulates its transcriptional activity Endocrinology 1999 140 1 392 397
44. Shao D., Rangwala S. M., Bailey S. T., Krakow S. L., Reginato M. J., Lazar M. A., Interdomain communication regulating ligand binding by PPAR-γ Nature 1998 396 6709 377 380
45. Camp H. S., Tafuri S. R., Regulation of peroxisome proliferator-activated receptor γactivity by mitogen-activated protein kinase Journal of Biological Chemistry 1997 272 16 10811 10816
46. Adams M., Reginato M. J., Shao D., Lazar M. A., Chatterjee V. K., Transcriptional activation by peroxisome proliferator-activated receptor γ is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site Journal of Biological Chemistry 1997 272 8 5128 5132
47. Han J., Hajjar D. P., Tauras J. M., Feng J., Gotto A. M. Jr., Nicholson A. C., Transforming growth factor-β1 (TGF-β1) and TGF-β2 decrease expression of CD36, the type B scavenger receptor, through mitogen-activated protein kinase phosphorylation of peroxisome proliferator-activated receptor-γ Journal of Biological Chemistry 2000 275 2 1241 1246
48. Rochette-Egly C., Nuclear receptors: integration of multiple signalling pathways through phosphorylation Cellular Signalling 2003 15 4 355 366
49. Floyd Z. E., Stephens J. M., Interferon-γ-mediated activation and ubiquitin-proteasome-dependent degradation of PPARγ in adipocytes Journal of Biological Chemistry 2002 277 6 4062 4068
50. Ristow M., Mller-Wieland D., Pfeiffer A., Krone W., Kahn C. R., Obesity associated with a mutation in a genetic regulator of adipocyte differentiation The New England Journal of Medicine 1998 339 14 953 959
51. Rangwala S. M., Rhoades B., Shapiro J. S.et al., Genetic modulation of PPARγ phosphorylation regulates insulin sensitivity Developmental Cell 2003 5 4 657 663
52. Wu Z., Xie Y., Morrison R. F., Bucher N. L. R., Farmer S. R., PPAR induces the insulin-dependent glucose transporter GLUT4 in the absence of C/EBPγ during the conversion of 3T3 fibroblasts into adipocytes Journal of Clinical Investigation 1998 101 1 22 32
53. Baumann C. A., Chokshi N., Saltiel A. R., Ribon V., Cloning and characterization of a functional peroxisome proliferator activator receptor-γ-responsive element in the promoter of the CAP gene Journal of Biological Chemistry 2000 275 13 9131 9135
54. Rieusset J., Auwerx J., Vidal H., Regulation of gene expression by activation of the peroxisome proliferator-activated receptor with rosiglitazone (BRL 49653) in human adipocytes Biochemical and Biophysical Research Communications 1999 265 1 265 271
55. Furuta M., Yano Y., Gabazza E. C. et al., Troglitazone improves GLUT4 expression in adipose tissue in an animal model of obese type 2 diabetes mellitus Diabetes Research and Clinical Practice 2002 56 3 159 171
56. Armoni M., Kritz N., Harel C. et al., Peroxisome proliferator-activated receptor-γ represses GLUT4 promoter activity in primary adipocytes, and rosiglitazone alleviates this effect Journal of Biological Chemistry 2003 278 33 30614 30623
57. Ribon V., Johnson J. H., Camp H. S., Saltiel A. R., Thiazolidinediones and insulin resistance: peroxisome proliferator-activated receptor activation stimulates expression of the CAP gene Proceedings of the National Academy of Sciences of the United States of America 1998 95 25 14751 14756
58. Liao W., Nguyen M. T. A., Yoshizaki T. et al., Suppression of PPAR-γ attenuates insulin-stimulated glucose uptake by affecting both GLUT1 and GLUT4 in 3T3-L1 adipocytes American Journal of Physiology 2007 293 1 E219 E227
59. Norris A. W., Chen L., Fisher S. J. et al., Muscle-specific PPARγ-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones Journal of Clinical Investigation 2003 112 4 608 618
60. Hevener A. L., He W., Barak Y.et al., Muscle-specific Pparg deletion causes insulin resistance Nature Medicine 2003 9 12 1491 1497
61. Kim K. Y., Cho H. S., Jung W. H., Kim S. S., Cheon H. G., Phosphatase and tensin homolog deleted on chromosome 10 suppression is an important process in peroxisome proliferator-activated receptor-β signaling in adipocytes and myotubes Molecular Pharmacology 2007 71 6 1554 1562
62. Luquet S., Lopez-Soriano J., Holst D. et al., Peroxisome proliferator-activated receptor δcontrols muscle development and oxidative capability FASEB Journal 2003 17 15 2299 2301
63. Wang Y.-X., Lee C.-H., Tiep S. et al., Peroxisome-proliferator-activated receptor δactivates fat metabolism to prevent obesity Cell 2003 113 2 159 170
64. Krämer D. K., Al-Khalili L., Perrini S. et al., Direct activation of glucose transport in primary human myotubes after activation of peroxisome proliferator-activated receptorδ Diabetes 2005 54 4 1157 1163
65. Koutnikova H., Cock T.-A., Watanabe M. et al., Compensation by the muscle limits the metabolic consequences of lipodystrophy in PPARγ hypomorphic mice Proceedings of the National Academy of Sciences of the United States of America 2003 100 24 14457 14462
66. He W., Barak Y., Hevener A. et al., Adipose-specific peroxisome proliferator-activated receptor γ knockout causes insulin resistance in fat and liver but not in muscle Proceedings of the National Academy of Sciences of the United States of America 2003 100 26 15712 15717
67. Jones J. R., Barrick C., Kim K.-A.et al., Deletion of PPAR in adipose tissues of mice protects against high fat diet-induced obesity and insulin resistance Proceedings of the National Academy of Sciences of the United States of America 2005 102 17 6207 6212
68. Chawla A., Schwarz E. J., Dimaculangan D. D., Lazar M. A., Peroxisome proliferator-activated receptor (PPAR)γ: adipose-predominant expression and induction early in adipocyte differentiation Endocrinology 1994 135 2 798 800
69. Tontonoz P., Hu E., Spiegelman B. M., Stimulation of adipogenesis in fibroblasts by PPAR 2, a lipid-activated transcription factor Cell 1994 79 7 1147 1156
70. Tontonoz P., Nagy L., Alvarez J. G. A., Thomazy V. A., Evans R. M., PPARγ promotes monocyte/macrophage differentiation and uptake of oxidized LDL Cell 1998 93 2 241 252
71. Tontonoz P., Hu E., Devine J., Beale E. G., Spiegelman B. M., PPARγ2 regulates adipose expression of the phosphoenolpyruvate carboxykinase gene Molecular and Cellular Biology 1995 15 1 351 357
72. Schoonjans K., Peinado-Onsurbe J., Lefebvre A.-M. et al., PPARα and PPARγ activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene The EMBO Journal 1996 15 19 5336 5348
73. Imai T., Takakuwa R., Marchand S. et al., Peroxisome proliferator- activated receptor is required in mature white and brown adipocytes for their survival in the mouse Proceedings of the National Academy of Sciences of the United States of America 2004 101 13 4543 4547
74. Gurnell M., Peroxisome proliferator-activated receptor γ and the regulation of adipocyte function: lesssons from human genetic studies Best Practice and Research: Clinical Endocrinology and Metabolism 2005 19 4 501 523
75. Wu Z., Bucher N. L. R., Farmer S. R., Induction of peroxisome proliferator-activated receptor γ during the conversion of 3T3 fibroblasts into adipocytes is mediated by C/EBPβ , C/EBPδ, and glucocorticoids Molecular and Cellular Biology 1996 16 8 4128 4136
76. Wu Z., Xie Y., Bucher N. L. R., Farmer S. R., Conditional ectopic expression of C/EBPβ in NIH-3T3 cells induces PPARγ and stimulates adipogenesis Genes and Development 1995 9 19 2350 2363
77. Perrini S., Laviola L., Cignarelli A. et al., Fat depot-related differences in gene expression, adiponectin secretion, and insulin action and signalling in human adipocytes differentiated in vitro from precursor stromal cells Diabetologia 2008 51 1 155 164
78. Kim J. B., Spiegelman B. M., ADD1/SREBP1 promotes adipocyte differentiation and gene expression linked to fatty acid metabolism Genes and Development 1996 10 9 1096 1107
79. Fajas L., Schoonjans K., Gelman L. et al., Regulation of peroxisome proliferator-activated receptor γ expression by adipocyte differentiation and determination factor 1/sterol regulatory element binding protein 1: implications for adipocyte differentiation and metabolism Molecular and Cellular Biology 1999 19 8 5495 5503
80. Wu Z., Rosen E. D., Brun R. et al., Cross-regulation of C/EBPα and PPARγ controls the transcriptional pathway of adipogenesis and insulin sensitivity Molecular Cell 1999 3 2 151 158
81. Elbrecht A., Chen Y., Cullinan C. A. et al., Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors γ1 and γ2 Biochemical and Biophysical Research Communications 1996 224 2 431 437
82. Gimble J. M., Robinson C. E., Wu X. et al., Peroxisome proliferator-activated aeceptor-γ activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells Molecular Pharmacology 1996 50 5 1087 1094
83. Torti F. M., Dieckmann B., Beutler B., A macrophage factor inhibits adipocyte gene expression: an in vitro model of cachexia Science 1985 229 4716 867 869
84. Stephens J. M., Pekala P. H., Transcriptional repression of the C/EBP- and GLUT4 genes in 3T3-L1 adipocytes by tumor necrosis factor-. Regulation is coordinate and independent of protein synthesis Journal of Biological Chemistry 1992 267 19 13580 13584
85. Szalkowski D., White-Carrington S., Berger J., Zhang B., Antidiabetic thiazolidinediones block the inhibitory effect of tumor necrosis factor- on differentiation, insulin-stimulated glucose uptake, and gene expression in 3T3-L1 cells Endocrinology 1995 136 4 1474 1481
86. Zhang B., Berger J., Hu E. et al., Negative regulation of peroxisome proliferator-activated receptor- gene expression contributes to the antiadipogenic effects of tumor necrosis factor-α Molecular Endocrinology 1996 10 11 1457 1466
87. Ron D., Brasier A. R., McGehee R. E. Jr., Habener J. F., Tumor necrosis factor-induced reversal of adipocytic phenotype of 3T3-L1 cells is preceded by a loss of nuclear CCAAT/enhancer binding protein (C/EBP) Journal of Clinical Investigation 1992 89 1 223 233
88. Kallen C. B., Lazar M. A., Antidiabetic thiazolidinediones inhibit leptin (ob) gene expression in 3T3-L1 adipocytes Proceedings of the National Academy of Sciences of the United States of America 1996 93 12 5793 5796
89. Hollenberg A. N., Susulic V. S., Madura J. P. et al., Functional antagonism between CCAAT/enhancer binding protein-α and peroxisome proliferator-activated receptor-γ on the leptin promoter Journal of Biological Chemistry 1997 272 8 5283 5290
90. Okuno A., Tamemoto H., Tobe K.et al., Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats Journal of Clinical Investigation 1998 101 6 1354 1361
91. Hu E., Liang P., Spiegelman B. M., AdipoQ is a novel adipose-specific gene dysregulated in obesity Journal of Biological Chemistry 1996 271 18 10697 10703
92. Berg A. H., Combs T. P., Scherer P. E., ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism Trends in Endocrinology and Metabolism 2002 13 2 84 89
93. Yu J. G., Javorschi S., Hevener A. L. et al., The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects Diabetes 2002 51 10 2968 2974
94. Pajvani U. B., Hawkins M., Combs T. P. et al., Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity Journal of Biological Chemistry 2004 279 13 12152 12162
95. Yamauchi T., Kamon J., Minokoshi Y. et al., Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase Nature Medicine 2002 8 11 1288 1295
96. Nawrocki A. R., Rajala M. W., Tomas E. et al., Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor γagonists Journal of Biological Chemistry 2006 281 5 2654 2660
97. Steppan C. M., Bailey S. T., Bhat S. et al., The hormone resistin links obesity to diabetes Nature 2001 409 6818 307 312
98. Banerjee R. R., Rangwala S. M., Shapiro J. S.et al., Regulation of fasted blood glucose by resistin Science 2004 303 5661 1195 1198
99. Uysal K. T., Wiesbrock S. M., Marino M. W., Hotamisligil G. S., Protection from obesity-induced insulin resistance in mice lacking TNF- function Nature 1997 389 6651 610 614
100. Kintscher U., Law R. E., PPARγ-mediated insulin sensitization: the importance of fat versus muscle American Journal of Physiology 2005 288 2 E287 E291
101. Tontonoz P., Spiegelman B. M., Fat and beyond: the diverse biology of PPARγ Annual Review of Biochemistry 2008 77 289 312
102. Gavrilova O., Haluzik M., Matsusue K. et al., Liver peroxisome proliferator-activated receptor contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass Journal of Biological Chemistry 2003 278 36 34268 34276
103. Yu S., Matsusue K., Kashireddy P.et al., Adipocyte-specific gene expression and adipogenic steatosis in the mouse liver due to peroxisome proliferator-activated receptor γ1 (PPARγ1) overexpression Journal of Biological Chemistry 2003 278 1 498 505
104. Promrat K., Lutchman G., Uwaifo G. I. et al., A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis Hepatology 2004 39 1 188 196
105. Ratziu V., Giral P., Jacqueminet S. et al., Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled fatty liver improvement with rosiglitazone therapy (FLIRT) trial Gastroenterology 2008 135 1 100 110
106. Belfort R., Harrison S. A., Brown K. et al., A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis The New England Journal of Medicine 2006 355 22 2297 2307
107. Bays H., Mandarino L., DeFronzo R. A., Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach Journal of Clinical Endocrinology and Metabolism 2004 89 2 463 478
108. Schoonjans K., Peinado-Onsurbe J., Lefebvre A.-M. et al., PPARα and PPARγ activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene The EMBO Journal 1996 15 19 5336 5348
109. Frohnert B. I., Hui T. Y., Bernlohr D. A., Identification of a functional peroxisome proliferator-responsive element in the murine fatty acid transport protein gene Journal of Biological Chemistry 1999 274 7 3970 3977
110. Guan H.-P., Yong L., Jensen M. V., Newgard C. B., Steppan C. M., Lazar M. A., A futile metabolic cycle activated in adipocytes by antidiabetic agents Nature Medicine 2002 8 10 1122 1128
111. Tordjman J., Chauvet G., Quette J., Beale E. G., Forest C., Antoine B., Thiazolidinediones block fatty acid release by inducing glyceroneogenesis in fat cells Journal of Biological Chemistry 2003 278 21 18785 18790
112. Buse J. B., Tan M. H., Prince M. J., Erickson P. P., The effects of oral anti-hyperglycaemic medications on serum lipid profiles in patients with type 2 diabetes Diabetes, Obesity and Metabolism 2004 6 2 133 156
113. Miyazaki Y., Mahankali A., Wajcberg E., Bajaj M., Mandarino L. J., DeFronzo R. A., Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients Journal of Clinical Endocrinology and Metabolism 2004 89 9 4312 4319
114. Matsui J., Terauchi Y., Kubota N. et al., Pioglitazone reduces islet triglyceride content and restores impaired glucose-stimulated insulin secretion in heterozygous peroxisome proliferator-activated receptor-γ-deficient mice on a high-fat diet Diabetes 2004 53 11 2844 2854
115. Lin C.-Y., Gurlo T., Haataja L., Hsueh W. A., Butler P. C., Activation of peroxisome proliferator-activated receptor-γ by rosiglitazone protects human islet cells against human islet amyloid polypeptide toxicity by a phosphatidylinositol 3′ -kinase-dependent pathway Journal of Clinical Endocrinology and Metabolism 2005 90 12 6678 6686
116. Lalloyer F., Vandewalle B., Percevault F., Peroxisome proliferator-activated receptor α improves pancreatic adaptation to insulin resistance in obese mice and reduces lipotoxicity in human islets Diabetes 2006 55 6 1605 1613